| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | General Counsel | Common Stock | 4K | $2.24K | $0.56 | Aug 23, 2022 | Direct |
| Aeglea BioTherapeutics, Inc. | General Counsel | Employee Stock Option (right to buy) | 500K | Feb 23, 2023 | Direct | ||
| ArriVent BioPharma, Inc. | General Counsel | Stock Option (right to buy) | 102K | Feb 3, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | Feb 3, 2025 | 1 | $0 | 4 | Feb 14, 2025 | General Counsel |
| AVBP | ArriVent Biopharma, Inc. | Jan 25, 2024 | 0 | $0 | 3 | Jan 25, 2024 | General Counsel |
| AGLE | Aeglea BioTherapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Feb 24, 2023 | General Counsel |
| AGLE | Aeglea BioTherapeutics, Inc. | Aug 23, 2022 | 1 | $0 | 4 | Aug 25, 2022 | Interim CEO & General Counsel |
| AGLE | Aeglea BioTherapeutics, Inc. | Aug 23, 2022 | 0 | $0 | 3 | Aug 25, 2022 | Interim CEO & General Counsel |